Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/36042
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nold-Petry C.A. | en |
dc.contributor.author | Cholewa M. | en |
dc.contributor.author | Berger P.J. | en |
dc.contributor.author | Young M.J. | en |
dc.contributor.author | Bourke J.E. | en |
dc.contributor.author | Pearson J.T. | en |
dc.contributor.author | Nold M.F. | en |
dc.contributor.author | Sehgal A. | en |
dc.contributor.author | Bui C.B. | en |
dc.contributor.author | Kolodziej M. | en |
dc.contributor.author | Lamanna E. | en |
dc.contributor.author | Elgass K. | en |
dc.contributor.author | Rudloff I. | en |
dc.contributor.author | Schwenke D.O. | en |
dc.contributor.author | Tsuchimochi H. | en |
dc.contributor.author | Kroon M.A.G.M. | en |
dc.contributor.author | Cho S.X. | en |
dc.contributor.author | Maksimenko A. | en |
dc.date.accessioned | 2021-05-14T12:12:41Z | en |
dc.date.available | 2021-05-14T12:12:41Z | en |
dc.date.copyright | 2019 | en |
dc.date.created | 20190726 | en |
dc.date.issued | 2019-07-26 | en |
dc.identifier.citation | Frontiers in Immunology. 10 (JULY) (no pagination), 2019. Article Number: 1480. Date of Publication: 2019. | en |
dc.identifier.issn | 1664-3224 (electronic) | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/36042 | en |
dc.description.abstract | Pulmonary hypertension secondary to bronchopulmonary dysplasia (BPD-PH) represents a major complication of BPD in extremely preterm infants for which there are currently no safe and effective interventions. The abundance of interleukin-1 (IL-1) is strongly correlated with the severity and long-term outcome of BPD infants and we have previously shown that IL-1 receptor antagonist (IL-1Ra) protects against murine BPD; therefore, we hypothesized that IL-1Ra may also be effective against BPD-PH. We employed daily injections of IL-1Ra in a murine model in which BPD/BPD-PH was induced by antenatal LPS and postnatal hyperoxia of 65% O2. Pups reared in hyperoxia for 28 days exhibited a BPD-PH-like disease accompanied by significant changes in pulmonary vascular morphology: micro-CT revealed an 84% reduction in small vessels (4-5 mum diameter) compared to room air controls; this change was prevented by IL-1Ra. Pulmonary vascular resistance, assessed at day 28 of life by echocardiography using the inversely-related surrogate marker time-to-peak-velocity/right ventricular ejection time (TPV/RVET), increased in hyperoxic mice (0.27 compared to 0.32 in air controls), and fell significantly with daily IL-1Ra treatment (0.31). Importantly, in vivo cine-angiography revealed that this protection afforded by IL-1Ra treatment for 28 days is maintained at day 60 of life. Despite an increased abundance of mediators of pulmonary angiogenesis in day 5 lung lysates, namely vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1), no difference was detected in ex vivo pulmonary vascular reactivity between air and hyperoxia mice as measured in precision cut lung slices, or by immunohistochemistry in alpha-smooth muscle actin (alpha-SMA) and endothelin receptor type-A (ETA) at day 28. Further, on day 28 of life we observed cardiac fibrosis by Sirius Red staining, which was accompanied by an increase in mRNA expression of galectin-3 and CCL2 (chemokine (C-C motif) ligand 2) in whole hearts of hyperoxic pups, which improved with IL-1Ra. In summary, our findings suggest that daily administration of the anti-inflammatory IL-1Ra prevents the increase in pulmonary vascular resistance and the pulmonary dysangiogenesis of murine BPD-PH, thus pointing to IL-1Ra as a promising candidate for the treatment of both BPD and BPD-PH.Copyright © 2019 Bui, Kolodziej, Lamanna, Elgass, Sehgal, Rudloff, Schwenke, Tsuchimochi, Kroon, Cho, Maksimenko, Cholewa, Berger, Young, Bourke, Pearson, Nold and Nold-Petry. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Frontiers Media S.A. (E-mail: info@frontiersin.org) | en |
dc.relation.ispartof | Frontiers in Immunology | en |
dc.title | Interleukin-1 receptor antagonist protects newborn mice against pulmonary hypertension. | en |
dc.type | Article | en |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.3389/fimmu.2019.01480 | en |
dc.publisher.place | Switzerland | en |
dc.identifier.source | 628548520 | en |
dc.identifier.institution | (Bui, Rudloff, Cho, Berger, Nold, Nold-Petry) Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia (Bui, Sehgal, Rudloff, Cho, Berger, Nold, Nold-Petry) Department of Paediatrics, Monash University, Clayton, VIC, Australia (Kolodziej) Faculty of Medicine, University of Rzeszow, Rzeszow, Poland (Lamanna, Kroon, Bourke) Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia (Elgass) Monash Micro Imaging, Hudson Institute of Medical Research, Clayton, VIC, Australia (Sehgal) Monash Newborn, Monash Children's Hospital, Melbourne, VIC, Australia (Schwenke) Department of Physiology-Heart Otago, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand (Tsuchimochi, Pearson) Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan (Kroon) Department of Pharmacy, Amsterdam UMC, Amsterdam, Netherlands (Maksimenko) Imaging and Medical Beamline, Australian Synchrotron, Clayton, VIC, Australia (Cholewa) Centre for Innovation and Transfer of Natural Sciences and Engineering Knowledge, University of Rzeszow, Rzeszow, Poland (Young) Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, VIC, Australia (Pearson) Department of Physiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia | en |
dc.description.address | C.A. Nold-Petry, Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia. E-mail: claudia.nold@hudson.org.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2019 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Anti-inflammatory therapy Bronchopulmonary dysplasia Interleukin-1 receptor antagonist Interventional immunology Neonatal immunity Preterm infants Pulmonary hypertension Pulmonary vascular resistance | en |
dc.identifier.authoremail | Nold-Petry C.A.; claudia.nold@hudson.org.au | en |
dc.description.grant | Organization: (MU) *Monash University* Organization No: 501100001779 Country: Australia No: CF14/3517 Organization: *National Heart Foundation of Australia* Organization No: 501100001030 Country: Australia | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
crisitem.author.dept | Paediatric - Neonatal (Monash Newborn) | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.